Cheapest Mounjaro vs Wegovy Saxenda - UK Price £124.99

Our Pricing

Wegovy or Saxenda vs Mounjaro: UK Price Comparison

Published on: June 03, 2026

When comparing wegovy or saxenda vs mounjaro uk price options, understanding both cost and clinical efficacy helps you make an informed choice. At Cured Pharmacy, we offer all three MHRA-licensed injectable treatments with transparent upfront pricing and free clinical assessment by UK-registered prescribers, so you can access the treatment that best suits your weight loss goals.

Understanding the Three Injectable Weight Loss Treatments

Mounjaro (tirzepatide), Wegovy (semaglutide), and Saxenda (liraglutide) represent three generations of injectable weight loss medications licensed by the MHRA for weight management in the UK. Each works by mimicking natural gut hormones that regulate appetite and blood sugar, but they differ significantly in their mechanisms, dosing schedules, and clinical outcomes [1].

Saxenda was the first daily GLP-1 receptor agonist approved for weight management, requiring once-daily injections. Wegovy, a higher-dose formulation of semaglutide, offers once-weekly dosing and demonstrated superior weight loss in head-to-head trials. Mounjaro represents the newest advancement as the first dual GIP/GLP-1 receptor agonist, activating two hormone pathways simultaneously [2].

Understanding these differences is essential when weighing up wegovy or saxenda vs mounjaro uk price alongside clinical effectiveness. While cost matters, the treatment that delivers better results may offer greater value over your weight loss journey.

Mounjaro vs Wegovy vs Saxenda: Clinical Efficacy Compared

In the SURMOUNT-1 trial, participants taking the highest Mounjaro dose achieved an average weight loss of 22.5% of their body weight over 72 weeks — the highest reduction seen in any obesity trial to date [1]. By comparison, the STEP-1 trial showed Wegovy users lost an average of 14.9% body weight over 68 weeks, whilst Saxenda trials demonstrated average reductions of 8-9% over 56 weeks [2][3].

These differences reflect the distinct mechanisms of action. Mounjaro's dual receptor activation targets both GIP and GLP-1 pathways, producing more pronounced effects on appetite suppression and metabolic regulation. Wegovy's once-weekly semaglutide formulation offers stronger GLP-1 activation than Saxenda's daily liraglutide, explaining the intermediate efficacy profile [4].

Which Treatment Delivers Best Results?

Clinical trial data suggests Mounjaro produces the greatest average weight loss, followed by Wegovy, then Saxenda. However, individual response varies significantly based on metabolic factors, adherence, lifestyle modifications, and tolerability. Some patients achieve excellent results with Saxenda or Wegovy whilst experiencing fewer side effects than they might with Mounjaro.

Your UK prescriber will assess your medical history, current medications, weight loss goals, and any contraindications during your free consultation. This personalised assessment ensures you receive the treatment most likely to deliver safe, effective results for your specific circumstances.

Wegovy or Saxenda vs Mounjaro UK Price: What You'll Pay

At Cured Pharmacy, Mounjaro starts from £124.99 per month, positioning it competitively within the UK market for this advanced dual-receptor treatment. Pricing reflects the prescribed dose strength, which your UK clinician determines based on your treatment progression and response.

When evaluating wegovy or saxenda vs mounjaro uk price, consider both the monthly cost and the clinical outcomes you're likely to achieve. A treatment that costs slightly more but delivers significantly better weight loss may represent better value over a six- to twelve-month programme. All three treatments require ongoing monthly prescriptions, so total programme cost depends on how long you continue treatment to reach and maintain your goal weight.

Cured Pharmacy guarantees the lowest prices in the UK, with transparent pricing displayed before your consultation. Unlike some providers, there are no hidden fees, subscription charges, or mandatory add-ons — just honest, upfront costs for genuine UK-licensed medications dispensed by our GPhC-registered pharmacy team.

Understanding Dose Escalation and Pricing

All three treatments follow dose escalation schedules to minimise gastrointestinal side effects. You'll typically start on the lowest dose and gradually increase every four weeks until reaching your maintenance dose. Pricing may vary across dose strengths, with higher-strength pens generally costing more per month.

Your prescriber will explain the expected escalation timeline during your consultation. Most patients reach their maintenance dose within 16-20 weeks, after which monthly costs stabilise. This gradual approach improves tolerability whilst allowing your body to adapt to the medication's appetite-suppressing effects.

Dosing Schedules: Daily vs Weekly Injections

Saxenda requires once-daily subcutaneous injections, typically administered at the same time each day for consistent blood levels of liraglutide. This daily routine suits some patients who prefer smaller, more frequent doses, though others find daily injections less convenient than weekly alternatives.

Both Wegovy and Mounjaro offer once-weekly dosing, with injections administered on the same day each week. Many patients find weekly schedules easier to maintain long-term, reducing the mental burden of daily medication routines. Weekly injections also mean fewer injection site rotations and less frequent pen replacements [5].

When comparing wegovy or saxenda vs mounjaro uk price, factor in the convenience value of dosing frequency alongside monetary cost. Improved adherence with weekly injections may translate to better outcomes, potentially offsetting any price differences between treatments.

Side Effects and Tolerability Profiles

All three medications share similar gastrointestinal side effects due to their mechanism of slowing gastric emptying. Nausea, diarrhoea, constipation, and abdominal discomfort are the most commonly reported effects, typically most pronounced during dose escalation phases [1][2][3].

Clinical trial data suggests approximately 44% of Mounjaro users, 44% of Wegovy users, and 39% of Saxenda users experience nausea during treatment, though severity varies and symptoms often diminish as the body adapts. Starting with low doses and escalating gradually helps minimise these effects whilst maintaining efficacy [4].

Rare but serious side effects include pancreatitis, gallbladder disease, and thyroid C-cell tumours (seen in animal studies but not conclusively proven in humans). Your prescriber will screen for contraindications including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 before prescribing any GLP-1 treatment [6].

Managing Side Effects Effectively

Most gastrointestinal side effects can be managed through dietary modifications such as eating smaller meals, avoiding high-fat foods, staying well-hydrated, and not lying down immediately after eating. Your prescriber may also recommend temporarily pausing dose escalation if side effects become troublesome.

Superintendent pharmacist Tarun Kumar and our clinical team remain available throughout your treatment to provide guidance on managing side effects. If symptoms persist or worsen despite these measures, your prescriber may adjust your dose or consider switching to an alternative treatment that you tolerate better.

How to Access Treatment Through Cured Pharmacy

Accessing Mounjaro, Wegovy, or Saxenda through Cured Pharmacy begins with our free online consultation, which takes under three minutes to complete. You'll answer questions about your medical history, current medications, weight loss goals, and any contraindications that might affect prescribing decisions.

A UK-registered prescriber reviews your consultation within hours and determines whether treatment is clinically appropriate and safe for you. If approved, your prescription is sent directly to our GPhC-registered pharmacy (registration number 9012511), where our team dispenses genuine UK-licensed medication in discreet, unmarked packaging.

We offer next-day delivery across the UK, with medications shipped in temperature-controlled packaging to maintain efficacy. Your first delivery includes comprehensive patient information leaflets, injection technique guidance, and sharps disposal information. Ongoing prescriptions are managed through your online account, with monthly reminders ensuring you never run out of medication during your weight loss programme.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
4. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
5. Davies, M., Færch, L., Jeppesen, O. K., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
6. Medicines and Healthcare products Regulatory Agency. (2023). Glucagon-like peptide-1 (GLP-1) receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued. Drug Safety Update, 16(9). https://www.gov.uk/drug-safety-update [accessed 13 August 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on adherence to treatment, dietary modifications, and lifestyle changes. Past clinical trial results do not guarantee individual outcomes.